How reducing chemotherapy doses affects survival in older people with NSCLC who do not have targetable mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study reviews treatment records of patients aged 65 and older with stage IV NSCLC who lack EGFR, ALK, and ROS1 alterations and received at least one cycle of first-line chemotherapy. It compares chemotherapy dosing patterns, including dose reductions, with outcomes such as progression-free survival and overall survival. Patients who received targeted therapy or first-line immunotherapy or who have incomplete survival data are excluded. Data are collected from participating hospitals in Malaysia and Hong Kong and analyzed to identify associations between dose intensity and survival outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥65 years
* Histologically confirmed stage IV NSCLC
* Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
* Treated with at least ONE cycle of first-line chemotherapy

Exclusion Criteria:

* Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
* Incomplete survival data

Where it's running

• Queen Mary Hospital, The University of Hong Kong
  Hong Kong, Hong Kong Recruiting
• Hospital Tengku Ampuan Afzan
  Kuantan, Pahang, Malaysia Recruiting
• Hospital Wanita dan Kanak-Kanak Sabah
  Kota Kinabalu, Sabah, Malaysia Recruiting
• Universiti Malaya Medical Centre
  Kuala Lumpur, Malaysia Recruiting

Study contacts

• Principal investigator: Mau Ern Poh, MBBS — University of Malaya
• Study coordinator: Mau Ern Poh, MBBS
• Email: ernestpoh@um.edu.my
• Phone: +60379494422

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New total-body PET scanner test in people with NSCLC, head and neck cancer, and prostate cancer

  Researchers are testing a new total-body PET scanner called Biograph Vision Quadra to see if it provides clearer images and more information than standard PET/CT in people with certain cancers.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07690917

• SCTB14 as first-line therapy for advanced NSCLC

  This trial will test whether SCTB14 works better than pembrolizumab as first treatment for adults with unresectable locally advanced or metastatic, driver-gene–negative NSCLC whose tumors have PD-L1 TPS ≥10%.

  Recruiting Phase 3 Sinocelltech Ltd. · Shanghai, Shanghai Municipality · NCT07362459

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.